Literature DB >> 22405627

Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturally-occurring porcine endogenous retrovirus A.

Peter M Mazari1, Takele Argaw, Leonardo Valdivieso, Xia Zhang, Katherine T Marcucci, Daniel R Salomon, Carolyn A Wilson, Monica J Roth.   

Abstract

In vitro screening of randomized FeLV Envelope libraries identified the CP isolate, which enters cells through HuPAR-1, one of two human receptors utilized by porcine endogenous retrovirus-A (PERV-A), a distantly related gammaretrovirus. The CP and PERV-A Envs however, share little amino acid homology. Their receptor utilization was examined to define the common receptor usage of these disparate viral Envs. We demonstrate that the receptor usage of CP extends to HuPAR-2 but not to the porcine receptor PoPAR, the cognate receptor for PERV-A. Reciprocal interference between virus expressing CP and PERV-A Envs was observed on human cells. Amino acid residues localized to within the putative second extracellular loop (ECL-2) of PAR-1 and PAR-2 are found to be critical for CP envelope function. Through a panel of receptor chimeras and point mutations, this area was also found to be responsible for the differential usage of the PoPAR receptor between CP and PERV-A. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405627      PMCID: PMC3572736          DOI: 10.1016/j.virol.2012.02.012

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  Targeting a retroviral vector in the absence of a known cell-targeting ligand.

Authors:  Keith Bupp; Monica J Roth
Journal:  Hum Gene Ther       Date:  2003-11-01       Impact factor: 5.695

2.  Extended analysis of the in vitro tropism of porcine endogenous retrovirus.

Authors:  C A Wilson; S Wong; M VanBrocklin; M J Federspiel
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  The mechanism of interference between an avian leukosis virus and Rous sarcoma virus. II. Early steps of infection by RSV of cells under conditions of interference.

Authors:  F T Steck; H Rubin
Journal:  Virology       Date:  1966-08       Impact factor: 3.616

4.  Viral and cellular factors governing hamster cell infection by murine and gibbon ape leukemia viruses.

Authors:  C A Wilson; M V Eiden
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Partial dissociation of subgroup C phenotype and in vivo behaviour in feline leukaemia viruses with chimeric envelope genes.

Authors:  M A Rigby; J L Rojko; M A Stewart; G J Kociba; C M Cheney; L J Rezanka; L E Mathes; J R Hartke; O Jarrett; J C Neil
Journal:  J Gen Virol       Date:  1992-11       Impact factor: 3.891

6.  Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus.

Authors:  Anna L Barnett; David L Wensel; Weihua Li; Deborah Fass; James M Cunningham
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Identification of receptors for pig endogenous retrovirus.

Authors:  Thomas A Ericsson; Yasuhiro Takeuchi; Christian Templin; Gary Quinn; Shelli F Farhadian; James C Wood; Beth A Oldmixon; Kristen M Suling; Jennifer K Ishii; Yoshinori Kitagawa; Takayuki Miyazawa; Daniel R Salomon; Robin A Weiss; Clive Patience
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-09       Impact factor: 11.205

8.  Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus.

Authors:  Y Takeuchi; R G Vile; G Simpson; B O'Hara; M K Collins; R A Weiss
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Detection of receptor-specific murine leukemia virus binding to cells by immunofluorescence analysis.

Authors:  M J Kadan; S Sturm; W F Anderson; M A Eglitis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Suboptimal porcine endogenous retrovirus infection in non-human primate cells: implication for preclinical xenotransplantation.

Authors:  Giada Mattiuzzo; Yasuhiro Takeuchi
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

View more
  7 in total

1.  Construction of a gammaretrovirus with a novel tropism and wild-type replication kinetics capable of using human APJ as entry receptor.

Authors:  Shervin Bahrami; Kristina Pagh; Ditte Ejegod; Mogens Duch; Martin Tolstrup; Finn Skou Pedersen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

2.  Role of Cysteines in Stabilizing the Randomized Receptor Binding Domains within Feline Leukemia Virus Envelope Proteins.

Authors:  Leonardo Valdivieso-Torres; Anindita Sarangi; Jillian Whidby; Joseph Marcotrigiano; Monica J Roth
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

Review 3.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

4.  MLV based viral-like-particles for delivery of toxic proteins and nuclear transcription factors.

Authors:  Dai-Tze Wu; Monica J Roth
Journal:  Biomaterials       Date:  2014-07-03       Impact factor: 12.479

5.  Directed Molecular Evolution of an Engineered Gammaretroviral Envelope Protein with Dual Receptor Use Shows Stable Maintenance of Both Receptor Specificities.

Authors:  Kristina Pagh Friis; Xavier Iturrioz; Jonas Thomsen; Rodrigo Alvear-Perez; Shervin Bahrami; Catherine Llorens-Cortes; Finn Skou Pedersen
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

6.  Gene delivery in a mouse xenograft of a retargeted retrovirus to a solid 143B osteosarcoma.

Authors:  Xia Zhang; Anindita Sarangi; Dai-Tze Wu; Jaya Kanduri; Monica J Roth
Journal:  Virol J       Date:  2013-06-14       Impact factor: 4.099

Review 7.  Porcine Endogenous Retrovirus (PERV) - Molecular Structure and Replication Strategy in the Context of Retroviral Infection Risk of Human Cells.

Authors:  Krzysztof Łopata; Emilia Wojdas; Roman Nowak; Paweł Łopata; Urszula Mazurek
Journal:  Front Microbiol       Date:  2018-04-11       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.